Presenters
Experienced Academic Leader and Entrepreneur
Prof. Andrew Coats
Course Details
Prof. Andrew Coats shares the topic on the guidelines recommendation for T2D and CVD. This includes the ESC guidelines recommendation for glucose lowering therapies with established CV benefits. The different SGLT2i trials on T2D were also discussed as well as the benefits of empagliflozin for patients with T2D and CVD.
Estimated time of Completion: 22 Mins
CPD Points: 1 CPD point
Empagliflozin in T2D and CVD Course Outline
Section 1
- What do guidelines recommend?
- The 2019 ESC Guidelines recommendation.
- Clinical recommendations and guidelines support the use of SGLT2i inhibitors, independent of glucose control, in patients with T2D with indicators of high risk or established ASCVD, CKD, or HF.
Section 2
- Empagliflozin shows beneficial effects on CRM systems at early and progressive stages of disease in patients with T2D.
- Consistent Reductions in CV, HF and kidney outcomes were observed with SGLT2i in patients with T2D and either CVD and high CV risk.
- Rates of predefined AEs of special interest.
Section 3
- What does CV protection really mean for T2D patients?
- The effects of empagliflozin on CV death were seen as early as Day 59 (post hoc).
- Effects of empagliflozin on first HHF or CV death was seen as early as Day 27 (post hoc analysis).
- It is estimated that a 60-yr old patient with T2D and established CV disease could, on average, live 2.5 years longer when treated with empagliflozin.